JP2024533291A5 - - Google Patents
Info
- Publication number
- JP2024533291A5 JP2024533291A5 JP2024515026A JP2024515026A JP2024533291A5 JP 2024533291 A5 JP2024533291 A5 JP 2024533291A5 JP 2024515026 A JP2024515026 A JP 2024515026A JP 2024515026 A JP2024515026 A JP 2024515026A JP 2024533291 A5 JP2024533291 A5 JP 2024533291A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- unsubstituted
- pharmaceutical composition
- composition according
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241891P | 2021-09-08 | 2021-09-08 | |
| US63/241,891 | 2021-09-08 | ||
| PCT/EP2022/058574 WO2023036473A1 (en) | 2021-09-08 | 2022-03-31 | Combination drug therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533291A JP2024533291A (ja) | 2024-09-12 |
| JP2024533291A5 true JP2024533291A5 (https=) | 2025-03-25 |
Family
ID=81325378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515026A Pending JP2024533291A (ja) | 2021-09-08 | 2022-03-31 | 併用薬物療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240366655A1 (https=) |
| EP (1) | EP4398871A1 (https=) |
| JP (1) | JP2024533291A (https=) |
| KR (1) | KR20240052775A (https=) |
| AU (1) | AU2022342266B2 (https=) |
| CA (1) | CA3231021A1 (https=) |
| WO (1) | WO2023036473A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
| CN121285372A (zh) * | 2023-04-28 | 2026-01-06 | 耶鲁大学 | 治疗创伤后应激障碍的组合物和方法 |
| US12303503B1 (en) | 2023-11-16 | 2025-05-20 | Biobina Llc | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain |
| WO2025123137A1 (en) * | 2023-12-15 | 2025-06-19 | 10763942 Canada Inc. (Dba. Purminds Neuropharma) | Heterocyclic compounds and methods of preparation thereof |
| WO2025170990A1 (en) * | 2024-02-06 | 2025-08-14 | Atai Therapeutics, Inc. | Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20220304980A1 (en) * | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
-
2022
- 2022-03-31 JP JP2024515026A patent/JP2024533291A/ja active Pending
- 2022-03-31 US US18/688,125 patent/US20240366655A1/en active Pending
- 2022-03-31 WO PCT/EP2022/058574 patent/WO2023036473A1/en not_active Ceased
- 2022-03-31 KR KR1020247008355A patent/KR20240052775A/ko active Pending
- 2022-03-31 AU AU2022342266A patent/AU2022342266B2/en active Active
- 2022-03-31 EP EP22716971.1A patent/EP4398871A1/en active Pending
- 2022-03-31 CA CA3231021A patent/CA3231021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533291A5 (https=) | ||
| JP2025510942A5 (https=) | ||
| JP2023540017A5 (https=) | ||
| JP2024540282A5 (https=) | ||
| JP2024522065A5 (https=) | ||
| JP2023544724A5 (https=) | ||
| IL297492A (en) | Deuterated tryptamine derivatives and methods of use | |
| CN1122018C (zh) | 作为药用活性成分的6－二甲氨基甲基－1－苯基环己烷化合物 | |
| CN100430394C (zh) | N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用 | |
| JP2025505745A5 (https=) | ||
| JP2021519267A5 (https=) | ||
| JP2013544850A5 (https=) | ||
| JP2007508361A5 (https=) | ||
| JP2007516941A5 (https=) | ||
| JP2008524262A5 (https=) | ||
| RU2259349C2 (ru) | Замещенные производные 2-диалкиламиноалкилбифенила | |
| JP2002523491A5 (https=) | ||
| JP2011509297A5 (https=) | ||
| JP2005523334A5 (https=) | ||
| JP2009500425A5 (https=) | ||
| JP2002525280A5 (https=) | ||
| CN1805956A (zh) | 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途 | |
| JP2025502208A5 (https=) | ||
| JP2008502651A (ja) | モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペリジン誘導体及びその使用 | |
| CN1307574A (zh) | 作为5－羟色胺能药物的吲哚基衍生物 |